Medication info

Hallym Heparin Sodium Injection

Prescription medicationIntravenous injection · Subcutaneous injection
Ingredient · strength
Heparin Sodium›Strength being verified
Manufacturer / importer
Hallym Pharmaceutical Co., Ltd.
Appearance
A colorless to pale yellow transparent liquid contained in a colorless, transparent vial.
Packaging
5mL/vial x 10 vials
Approval status
Active

MFDS item code 198200870 · Notified 1982.11.12 · Insurance code 645302871

Summary

Main use
Prevention and treatment of thrombosis and embolism; diagnosis and treatment of coagulation disorders; prevention of blood coagulation
Who receives it
Adults
Adult administration
Usually administered by intravenous injection or added to the perfusate during extracorporeal circulation of blood. Although the effect appears immediately after administration, sensitivity to heparin varies considerably among individuals. Therefore, perform a heparin sensitivity test before administration and measure blood coagulation time after administration to determine the maintenance dose. Usually, after use, maintain blood coagulation time at 15 ~ 20 minutes or longer; determine the dose according to the case, indication, or purpose. 1. Extracorporeal circulation 1) Artificial kidney (1) Systemic heparinization: Before starting dialysis, administer 1,000 ~ 5,000 IU of heparin sodium. After dialysis begins, administer 500 ~ 1,500 IU per hour continuously, or administer additional intermittent doses of 500 ~ 1,500 IU every hour. (2) Regional heparinization: Administer 1,500 ~ 2,500 IU per hour of this drug continuously; neutralize with protamine sulfate during extracorporeal circulation. 2) Blood perfusion using a heart-lung machine : Administer 150 ~ 300 IU of this drug per kg of body weight and add more as appropriate if extracorporeal circulation is prolonged. After extracorporeal circulation, use protamine sulfate to prevent postoperative bleeding and neutralize the action of heparin. 2. Intravenous infusion Dissolve 10,000 ~ 30,000 IU of this drug in 1,000 mL of 5 % dextrose injection, normal saline, or Ringer's solution. Infuse at a rate of approximately 30 drops per minute, and when the whole-blood clotting time reaches 2 ~ 3 times the pretreatment value, infuse at a rate of approximately 20 drops per minute. 3. Intermittent intravenous injection Administer 5,000 ~ 10,000 IU of this drug intravenously every 4 ~ 8 hours. Starting 3 hours after initiation of treatment, measure whole-blood clotting time every 2 ~ 4 hours and adjust the dose to maintain it at 2 ~ 3 times the pretreatment value. 4. Subcutaneous injection Administer 10,000 ~ 20,000 IU of this drug subcutaneously, followed by maintenance doses of 15,000 ~ 20,000 IU every 12 hours. Use a different injection site each time to prevent hematoma. 5. Blood transfusion and blood tests For blood transfusion, usually use 400 ~ 500 IU of this drug per 100 mL of blood. For blood tests, use 100 IU per 20 ~ 30 mL of blood.

Ingredients

Manufacturer
Hallym Pharmaceutical Co., Ltd.

Efficacy & effects

Prevention and treatment of thrombosis and embolism; diagnosis and treatment of coagulation disorders; prevention of blood coagulation

  • Thrombosis
  • pulmonary embolism
  • embolic atrial fibrillation
  • acute coagulation disorders
  • chronic coagulation disorders
  • blood coagulation
  • cerebral thrombosis
  • coronary artery occlusion
  • peripheral vascular embolism
View approved original text

This medication is used for the prevention of thrombosis and the treatment of postoperative thrombosis and pulmonary embolism. It is also effective for the prevention and treatment of embolic atrial fibrillation, diagnosis and treatment of acute and chronic coagulation disorders. It is used to prevent blood coagulation during vascular and cardiac surgeries, and to prevent cerebral thrombosis caused by cerebral hemorrhage. It is also applied to prevent blood coagulation during transfusions, extracorporeal circulation, and dialysis, as well as in the treatment of coronary artery occlusion and peripheral vascular embolism. Overall, this drug plays a very important role in preventing blood coagulation and treating related diseases.

How it is given

Adult administration

Usually administered by intravenous injection or added to the perfusate during extracorporeal circulation of blood. Although the effect appears immediately after administration, sensitivity to heparin varies considerably among individuals. Therefore, perform a heparin sensitivity test before administration and measure blood coagulation time after administration to determine the maintenance dose. Usually, after use, maintain blood coagulation time at 15 ~ 20 minutes or longer; determine the dose according to the case, indication, or purpose. 1. Extracorporeal circulation 1) Artificial kidney (1) Systemic heparinization: Before starting dialysis, administer 1,000 ~ 5,000 IU of heparin sodium. After dialysis begins, administer 500 ~ 1,500 IU per hour continuously, or administer additional intermittent doses of 500 ~ 1,500 IU every hour. (2) Regional heparinization: Administer 1,500 ~ 2,500 IU per hour of this drug continuously; neutralize with protamine sulfate during extracorporeal circulation. 2) Blood perfusion using a heart-lung machine : Administer 150 ~ 300 IU of this drug per kg of body weight and add more as appropriate if extracorporeal circulation is prolonged. After extracorporeal circulation, use protamine sulfate to prevent postoperative bleeding and neutralize the action of heparin. 2. Intravenous infusion Dissolve 10,000 ~ 30,000 IU of this drug in 1,000 mL of 5 % dextrose injection, normal saline, or Ringer's solution. Infuse at a rate of approximately 30 drops per minute, and when the whole-blood clotting time reaches 2 ~ 3 times the pretreatment value, infuse at a rate of approximately 20 drops per minute. 3. Intermittent intravenous injection Administer 5,000 ~ 10,000 IU of this drug intravenously every 4 ~ 8 hours. Starting 3 hours after initiation of treatment, measure whole-blood clotting time every 2 ~ 4 hours and adjust the dose to maintain it at 2 ~ 3 times the pretreatment value. 4. Subcutaneous injection Administer 10,000 ~ 20,000 IU of this drug subcutaneously, followed by maintenance doses of 15,000 ~ 20,000 IU every 12 hours. Use a different injection site each time to prevent hematoma. 5. Blood transfusion and blood tests For blood transfusion, usually use 400 ~ 500 IU of this drug per 100 mL of blood. For blood tests, use 100 IU per 20 ~ 30 mL of blood.

Precautions

This drug is very potent and should only be used under strict medical supervision. Particular caution should be exercised when administering this drug to patients with conditions that carry a high risk of bleeding. Bleeding can occur in almost any part of the body and can sometimes result in life-threatening severe bleeding. Rarely, bleeding can occur behind the adrenal glands, ovaries, or in the peritoneal cavity, leading to serious complications such as acute adrenal insufficiency. The benzyl alcohol component in this drug can cause fatal respiratory issues in premature infants, so it should not be used in newborns or preterm infants. It should not be administered to patients with known allergies to this drug or its ingredients, or to those with abnormal blood coagulation test results. Patients with bleeding or bleeding tendencies, severe liver or kidney disease, or those who have recently undergone brain or eye surgery should not use this drug. It is also contraindicated in patients who have received spinal or epidural anesthesia or have undergone lumbar puncture. Those with a history of thrombocytopenia or sensitivity to benzyl alcohol, especially in newborns and preterm infants, should not be treated with this medication. Caution should be exercised in using this drug in patients with consumptive coagulopathy, catheter insertion, women in late pregnancy, patients with severe retinal disease, impaired liver or kidney function, children, and the elderly. This drug can cause various side effects such as bleeding, thrombocytopenia, elevated liver enzymes, allergic reactions, skin issues, osteoporosis with long-term use, and decreased kidney function, so symptoms should be closely monitored during usage. In particular, thrombocytopenia can lead to severe thrombosis, thus platelet counts should be regularly evaluated, and usage should be stopped immediately if anomalies are found. Blood coagulation function should be monitored during treatment, and dosages adjusted accordingly; if bleeding occurs, administration should be temporarily suspended. Abruptly stopping the medication can increase the risk of thrombosis, therefore the dosage should be gradually reduced. If there is a high risk of bleeding or a rapid decrease in platelet count, the antidote protamine sulfate can be used to neutralize the effects of this drug. This medication can interact with multiple drugs, therefore caution is warranted when used in combination with acetylsalicylic acid, non-steroidal anti-inflammatory drugs, anticoagulants, etc., due to increased bleeding risks. During pregnancy, caution should be taken due to the risk of uterine and placental bleeding, and breastfeeding women also need to be careful because of the benzyl alcohol component. The safety for children has not been sufficiently established, and risks are higher for the elderly, therefore even greater caution should be exercised in these groups. In cases of overdose, bleeding may intensify, so medical personnel should be notified immediately and an antidote should be administered. During treatment, intramuscular injections should be avoided, and this drug should not be mixed and injected with antihistamines.

Side effects

Hemorrhage, life-threatening hemorrhage, adrenal hemorrhage causing acute adrenal insufficiency, ovarian hemorrhage, retroperitoneal hemorrhage, gastrointestinal bleeding, cerebral hemorrhage, thrombocytopenia, arterial and venous thrombosis, acute reversible thrombocytopathy, increased γ-GTP, increased LDH, increased AST, increased ALT, pruritus, urticaria, chills, fever, rhinitis, bronchial asthma, tearing, conjunctivitis, cyanosis, tachycardia, feeling of pressure, vascular neurogenic edema, nausea, vomiting, hypotension, dyspnea, bronchospasm, shock, alopecia, vitiligo, hemorrhagic necrosis, hypoaldosteronism, osteoporosis, rebound effect, dyslipidemia, renal function inhibition, localized painful hematoma, priapism, diabetes, hyperkalemia, hyperalkalemia, metabolic acidosis, elevated lipase, vascular spastic response, erythema, mild pain, ulcer

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to avoid contact with air, and it is best kept at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the drug's efficacy for a longer duration.

Appearance and packaging

Appearance

A colorless to pale yellow transparent liquid contained in a colorless, transparent vial.

Package unit

5mL/vial x 10 vials

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.